Insider Transactions in Q1 2025 at Alnylam Pharmaceuticals, Inc. (ALNY)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
496
-0.49%
|
$119,040
$240.7 P/Share
|
|
Feb 28
2025
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
935
-0.86%
|
$224,400
$240.7 P/Share
|
|
Feb 28
2025
|
Tolga Tanguler EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
513
-0.44%
|
$123,120
$240.7 P/Share
|
|
Feb 28
2025
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
796
-0.29%
|
$191,040
$240.7 P/Share
|
|
Feb 28
2025
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,900
-0.42%
|
$696,000
$240.7 P/Share
|
|
Feb 27
2025
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
1,908
+12.07%
|
-
|
|
Feb 27
2025
|
Tolga Tanguler EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,667
+10.09%
|
-
|
|
Feb 27
2025
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,908
+5.21%
|
-
|
|
Feb 27
2025
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,921
+6.34%
|
-
|
|
Feb 18
2025
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
1,548
-1.98%
|
$393,192
$254.26 P/Share
|
|
Feb 18
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
1,440
-2.06%
|
$365,760
$254.95 P/Share
|
|
Feb 14
2025
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
1,561
-0.9%
|
$402,738
$258.13 P/Share
|
|
Feb 14
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
SELL
Open market or private sale
|
Direct |
663
-0.38%
|
$171,054
$258.13 P/Share
|
|
Feb 14
2025
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
967
-0.24%
|
$249,486
$258.13 P/Share
|
|
Feb 14
2025
|
Yvonne Greenstreet Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,213
-0.12%
|
$312,954
$258.13 P/Share
|
|
Feb 13
2025
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
3,109
+17.08%
|
-
|
|
Feb 13
2025
|
Kevin Joseph Fitzgerald CSO & EVP, Head of Research |
BUY
Grant, award, or other acquisition
|
Direct |
2,103
+12.31%
|
-
|
|
Feb 13
2025
|
Jeffrey V. Poulton EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,109
+8.43%
|
-
|
|
Feb 13
2025
|
Yvonne Greenstreet Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,859
+4.46%
|
-
|
|
Jan 27
2025
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
SELL
Open market or private sale
|
Direct |
52,592
-81.44%
|
$14,988,720
$285.0 P/Share
|
|
Jan 27
2025
|
Pushkal Garg CMO & EVP Dev & Med Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
48,876
+32.77%
|
$4,301,088
$88.95 P/Share
|
|
Jan 23
2025
|
Phillip A Sharp Director |
SELL
Open market or private sale
|
Direct |
11,250
-100.0%
|
$3,093,750
$275.0 P/Share
|
|
Jan 23
2025
|
Phillip A Sharp Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+50.0%
|
$1,473,750
$131.21 P/Share
|